PM
NextG Cal is designed as a formula specifically for bone and teeth
health, consisting of the most essential nutrients including Calcium and
Phosphorous in the natural form Microcrystalline Hydroxyapatite (MCHA),
Vitamin D3 and Vitamin K1. The following will provide some basis
information about this formula and how it is different from other
calcium supplements.
Q:
What is MCHA and how is it different from other calcium, for eg calcium
citrate, which is generally known as the most absorbable form?
It is
true that there are so many different forms of calcium available on the
market, we need to understand them well as the form of calcium will
affect the calcium’s pharmacokinetic properties such as absorption.
Most
forms of calcium consist of calcium chelated to another organic compound
e.g. Calcium Citrate, Calcium Carbonate. The amount of elemental
calcium (Ca) will vary in the different calcium forms. Unlike these,
Microcrystalline Hydroxyapatite (MCHA) is a naturally derived calcium
extracted from bone (cow). Also unlike other calcium forms, it provides
calcium and phosphorus in a ratio of 2:1, physiologically similar to our
bones. Also contained in MCHA are the organic components of bones which
consist of primarily collagen and proteins, these are preserved in its
natural form and not destroyed in the manufacturing processes
(temperature setting and/or chemical solvents). The organic components
provide additional benefits; the collagen fibres impart their quality of
flexibility.
MCHA
has been shown to have a better bioavailability/absorption because the
calcium and phosphate are in optimal proportions and in microcrystalline
form [1-2], within a readily digestible protein matrix. There is some
evidence that accompanying dietary intake of proteins and their
hydrolysis products enhances calcium absorption. It has also been
recorded that in their natural environment, some animals boost calcium
by consuming bones in stress situations [3].
Clinical
trials further support MCHA’s superiority over other calcium forms
{Calcium carbonate CaCO3, tricalcium phosphate Ca3(PO4)2}, showing that
MCHA is more effective in slowing bone loss [4-5].
Q:
What is special about the MCHA in NextG Cal formula?
PM NextG Cal is manufactured using 100% Australian Bovine Raw material
in an Australian Government approved facility. Raw material and finished
product are both controlled by an Australian Therapeutic Goods
Adminsitration (TGA)’s GMP facility and have to undergo all the quality
control processes required for a pharmaceutical product in Australia.
Australia
is a clean and green country, and classified free from bovine
spongiform encephalophathy (BSE) and foot and mouth disease. This pure
Australian MCHA is in concentrated form and derived from young free
range Australian bovine bone (age <2 months).
It
contains Calcium and Phosphorous as well as many other trace elements
and collagen found naturally in bone. It is processed at biological
temperature to maintain the integrity of the component molecules.
Processing protocol specifically preclude the use of harsh chemicals,
solvents and high temperature. Below is a summary of its features and
benefits:
Features
|
Benefits |
| Microcrystalline structure |
Improve absorption |
| Ca/P ratio is 2:1 |
Correct natural ratio maximises incorporation |
| Natural protein matrix |
Presents Ca and P in a natural way |
| Rich in other essential minerals |
Provide additional health benefits |
| Manufactured at low temperature |
Retains integrity to maximise absorption |
| Bone derived from specified young animals (age <2 months) |
Ensures consistency in specification of product such as low level of
lead. |
Each
batch of finished product PM NextG Cal is always assayed to ensure that
both Calcium and Phosphorous is present in the amounts stated on the
label.
In this
particular product the hydroxyapatite is embedded in a protein matrix
containing collagen, substituent amino acids and glycosaminoglycans.
Many essential minerals and trace minerals are also found, such as
magnesium, silicon among others [6].
Q:
PM NextG Cal also includes Vitamin D3 and Vit K1, what for?
Vitamin D is also called “sunshine vitamin”, it is metabolised by the
body from sun exposure any time before 10am or after 3pm over summer
months, and is critical to bone health, the absorption of calcium, and
to overall health and development [7], including healthy heart. There is
evidence that 60 – 70% of Australians have deficient or insufficient
levels of vitamin D [8]. Deficiency status has also been reported in
different countries.
Vitamin
D deficiency causes osteomalacia (softening of the bones due to
defective mineralization) in adults, rickets in children and can
exacerbate osteoporosis [9]. Insufficient vitamin D reduces the
efficiency of intestinal calcium absorption by ~30-50% [9]. Vitamin D
has a critical role in maintaining a healthy mineralised skeleton for
children and adults [9]. Other problems include links between vitamin D
deficiencies and cardiovascular events[10].
The
major biological function of Vitamin D is to maintain the serum calcium
in the normal physiological range to preserve neuromuscular and cellular
functions [9]. Vitamin D maintains blood calcium levels by enhancing
the efficiency of intestinal calcium absorption and increasing the
mobilisation of stem cells to become osteoclasts that in turn mobilise
calcium stores from the bone [9]. As such, supplementation with vitamin D
assists with calcium absorption and this is especially important in
osteoporotic patients where calcium absorption can be hampered [11].
Clinical
trials further support the concurrent supplementation of Vitamin D and
Calcium, showing it reduces the risk of hip fractures and other
nonvertebral fractures [12], increase cortical bone thickness [13] .
Clinical
trials have also demonstrated that Vitamin K supplementation can
improve bone health [14]. Low dietary Vitamin K1 (phylloquinone) intake
has been associated with increased hip fracture risk [15-16]. Vitamin K
functions as a cofactor in the posttranslational carboxylation of a
number of bone proteins [17]. When vitamin K1 is supplemented with
Vitamin D, it may substantially contribute to reducing postmenopausal
bone loss at the site of the femoral neck [17].
Q:
Why does PM NextG Cal consist of both Vitamin D3 and Vitamin K1? Why not
just Vit D3 but not K1? Will it be as effective?
As discussed in the previous question, insufficient vitamin D causes the
efficiency of intestinal calcium absorption to decrease from ~30-50%
[9]. Co-administration of Vitamin D and Vitamin K1 could greatly
contribute to reducing postmenopausal bone loss at the site of the
femoral neck [14]. In the same study [14], the addition of Vitamin K to
Vitamin D reduced bone loss of femoral neck by 1.3% more than
supplementation without Vitamin K.
The
inclusion of Vitamin D3 and K1 will help achieve optimal calcium
absorption in PM NextG Cal, maximising the benefits of the MCHA
component and making the formula an optimum calcium supplementation.
PM
NextG Cal is listed with the Australian Therapeutic Goods Administration
(TGA) for sales in Australia and available for export to all other
countries. It is made in an Australian TGA’s GMP facility and adheres to
all GMP rules and procedures for medicinal products.
1.
Nilsen, K.H., M.I. Jayson, and A.S. Dixon, Microcrystalline calcium
hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a
controlled study. Br Med J, 1978. 2(6145): p. 1124.
2. Buclin, T., A.F. Jacquet, and P. Burckhardt, [Intestinal
absorption of calcium gluconate and oseine-mineral complex: an
evaluation by conventional analyses]. Schweiz Med Wochenschr, 1986.
116(50): p. 1780-3.
3. R., K. Historical review of microcrystalline hydroxyapatite
compound. in Osteoporosis, a multidisciplinary problem. 1983.
4. Ruegsegger, P., A. Keller, and M.A. Dambacher, Comparison of the
treatment effects of ossein-hydroxyapatite compound and calcium
carbonate in osteoporotic females. Osteoporos Int, 1995. 5(1): p. 30-4.
5. Albertazzi, P., et al., Comparison of the effects of two different
types of calcium supplementation on markers of bone metabolism in a
postmenopausal osteopenic population with low calcium intake: a
double-blind placebo-controlled trial. Climacteric, 2004. 7(1): p.
33-40.
6. Ltd, P.P.P., Microcrystalline Hydroxyapatite.
7. Halliday, J. (02-Jan-2008) UK kicks off winter vitamin D campaign.
8. Hall, R.S.a.L. (Dec 2007) Sunshine deficiency leads to vitamin D
crisis.
9. Holick, M.F., Vitamin D and bone health. J Nutr, 1996. 126(4
Suppl): p. 1159S-64S.
10. Daniells, S. (08-Jan-2008) Low vitamin D levels linked to
increased heart disease risk.
11. Munck, O., Osteoporosis Due to Malabsorption of Calcium
Responding Favourably to Large Doses of Vitamin D. Q J Med, 1964. 33: p.
209-21.
12. Chapuy, M.C., et al., Vitamin D3 and calcium to prevent hip
fractures in the elderly women. N Engl J Med, 1992. 327(23): p. 1637-42.
13. Epstein, O., et al., Vitamin D, hydroxyapatite, and calcium
gluconate in treatment of cortical bone thinning in postmenopausal women
with primary biliary cirrhosis. Am J Clin Nutr, 1982. 36(3): p. 426-30.
14. Weber, P., Vitamin K and bone health. Nutrition, 2001. 17(10): p.
880-7.
15. Feskanich, D., et al., Vitamin K intake and hip fractures in
women: a prospective study. Am J Clin Nutr, 1999. 69(1): p. 74-9.
16. Booth, S.L., et al., Dietary vitamin K intakes are associated
with hip fracture but not with bone mineral density in elderly men and
women. Am J Clin Nutr, 2000. 71(5): p. 1201-8.
17. Braam, L.A., et al., Vitamin K1 supplementation retards bone loss
in postmenopausal women between 50 and 60 years of age. Calcif Tissue
Int, 2003. 73(1): p. 21-6.